Explore

Trendline Trendline
Poxel Reports Increased Revenue for Q1 2026 Amid TWYMEEG® Sales Growth in Japan

Poxel Reports Increased Revenue for Q1 2026 Amid TWYMEEG® Sales Growth in Japan

Poxel Reports Increased Revenue for Q1 2026 Amid TWYMEEG® Sales Growth in Japan
Trendline Trendline
Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment

Lantern Pharma's HARMONIC Trial Receives FDA Support for Protocol Amendments in NSCLC Treatment
Trendline Trendline
Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026

Akari Therapeutics Reports Increased Net Loss in Q1 2026
Trendline Trendline
CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results

CEL-SCI Reports Progress in Multikine Development and Financial Results
Trendline Trendline
Pfizer Advances Pediatric Pneumococcal Vaccine Program with Promising Phase 2 Results

Pfizer Advances Pediatric Pneumococcal Vaccine Program with Promising Phase 2 Results

Pfizer Advances Pediatric Pneumococcal Vaccine Program with Promising Phase 2 Results
Trendline Trendline
Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform

Passkey Therapeutics Appoints New CMO to Advance Drug Combination Platform
Trendline Trendline
Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth

Sensei Biotherapeutics Advances Cancer Treatment Trials with PIKTOR, Reports Financial Growth
Trendline Trendline
Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate

Enveric Biosciences Reports Q1 2026 Financial Results and Advances Lead Drug Candidate
Trendline Trendline
ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage

ImmunityBio Secures Exclusive U.S. Rights to Tokyo Strain of BCG to Address Bladder Cancer Treatment Shortage
Trendline Trendline
ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer

ImmunityBio Secures U.S. Agreement for Tokyo Strain of BCG to Address Bladder Cancer
Trendline Trendline
Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations

Bronstein, Gewirtz Grossman, LLC Files Class Action Lawsuit Against Immutep Limited for Securities Violations
Rapid Read Rapid Read
ImmunityBio Secures U.S. Rights for Tokyo Strain of BCG to Address Shortage

ImmunityBio Secures U.S. Rights for Tokyo Strain of BCG to Address Shortage

ImmunityBio, Inc. has signed an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory for the Tokyo strain of BCG (Tokyo-172 BCG). This agreement aims to address the longstanding BCG shortage in the United States by providing a second potential source of BCG. The Tokyo strain has shown non-inferior efficacy compared to TICE BCG in a Phase III trial for high-grade non-muscle invasive bladder cancer. ImmunityBio plans to engage with the FDA to pursue approval for this strain, which has been used in Japan for nearly 30 years.